Resmed Inc (ASX:RMD) Closes FY2026 with Record Fourth Quarter Revenue

Sonal Goyal

17 September 2026 03:39 AM AEST

Resmed Inc (ASX:RMD) Closes FY2026 with Record Fourth Quarter Revenue

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Resmed reported fourth quarter fiscal 2026 Revenue of a record $1.5 billion, up 9% year-over-year (8% in constant currency)
Full year fiscal 2026 free Cash Flow was $1.6 billion, with more than $1.0 billion returned to shareholders through Buybacks and dividends
Q4 non-GAAP Diluted Earnings per Share rose 16% to $2.95, while GAAP diluted earnings per share increased 2% to $2.64
Full year 2026 gross Margin expanded by 90 basis points year-over-year, alongside a 16% increase in earnings per share

Resmed Inc (NYSE: RMD, ASX:RMD) is a global health technology company focused on sleep health, breathing health and healthcare in the home. This article reviews the company's fourth quarter and full year fiscal 2026 results, its core operations, sector context and developments shareholders are monitoring for fiscal 2027.

The share price was AUD 32.04 during the Trading session on 17 September 2026. The stock moved up by 0.44% during the trading session on 17 September 2026.

Company Business

Resmed develops and markets health technologies used in the diagnosis and treatment of sleep-disordered breathing and other respiratory conditions, along with a broader suite of digital health and out-of-hospital software solutions. Its product range includes continuous positive airway pressure devices, masks and accessories for the treatment of obstructive sleep apnea, alongside ventilation and other respiratory therapy devices used in home and clinical settings. The company also provides software-as-a-service platforms supporting care coordination across home medical equipment, home health and other out-of-hospital care settings. Resmed operates globally, with manufacturing, distribution and commercial operations serving patients, healthcare providers and durable medical equipment customers across multiple regions.

Sector Context

The sleep health and respiratory device sector is influenced by growing awareness and diagnosis rates of obstructive sleep apnea, reimbursement policies for durable medical equipment in markets such as the United States, and ongoing innovation in connected and digital health platforms. Companies in this sector operate under regulatory oversight from bodies including the U.S. Food and Drug Administration and equivalent international regulators. Currency movements are also relevant to reported results given the global nature of device Manufacturing and sales in this industry.

Recent Developments

Resmed announced its results for the fourth quarter and full year of fiscal 2026, for the period ended 30 June 2026, on 6 August 2026. Resmed's Chairman and CEO, Mick Farrell, said the company closed the fiscal year with fourth quarter results reflecting continued momentum in its global Business and sustained Demand for its products. Earlier in the fiscal year, the company reported third quarter results, for the quarter ended 31 March 2026, on 30 April 2026, citing 11% reported revenue growth and a 21% increase in earnings per share for that quarter. First quarter fiscal 2026 results, for the quarter ended 30 September 2025, were reported on 30 October 2025, with revenue of $1.3 billion, up 9%, and Operating Cash Flow of $457 million.

Financial Performance

For the fourth quarter of fiscal 2026, Resmed reported revenue of $1.5 billion, an increase of 9% year-over-year, or 8% on a constant currency basis. GAAP diluted earnings per share increased 2% to $2.64, while non-GAAP diluted earnings per share increased 16% to $2.95. For the full 2026 fiscal year, the company reported 9% reported revenue growth, 90 basis points of gross margin expansion and a 16% increase in earnings per share. Free cash flow for fiscal 2026 was $1.6 billion, and the company returned more than $1.0 billion to shareholders through share repurchases and dividends during the year, an increase of more than 70% on the prior year.

Risks to Consider

Resmed's results are subject to risks including currency movements given its global revenue and manufacturing base, and changes in reimbursement policy for durable medical equipment in key markets such as the United States. Competitive dynamics in the sleep and respiratory device market, ongoing regulatory requirements across the jurisdictions in which the company operates, and execution risk associated with continued Investment in digital health and software platforms are additional factors relevant to the business. The company's ongoing Capital return program, including share repurchases, is also subject to prevailing cash flow and Balance Sheet conditions.

What to Watch Next

Resmed's Chairman and CEO stated the company intends to Leverage its global scale and enhance its digital capabilities as it enters fiscal year 2027. The company's first quarter fiscal 2027 results, covering the quarter ending 30 September 2026, represent the next scheduled quarterly disclosure. Continued execution of the company's capital return program and further updates on its digital health and software offerings are among the items shareholders may continue to monitor.

Key Insights

Resmed's fiscal 2026 results show continued revenue and earnings growth across the year, culminating in record fourth quarter revenue. The company generated substantial free cash flow during the period, a portion of which was returned to shareholders through buybacks and dividends. Currency movements, reimbursement settings and continued investment in digital health capabilities are among the factors likely to influence the company's performance heading into fiscal 2027.

FAQs

Q: What does Resmed manufacture?

A:Resmed develops health technologies for sleep health and breathing health, including continuous positive airway pressure devices, masks and ventilation products, alongside digital health and out-of-hospital software platforms.

Q: What was Resmed's revenue for the fourth quarter of fiscal 2026?

A:Resmed reported fourth quarter fiscal 2026 revenue of $1.5 billion, up 9% year-over-year, or 8% on a constant currency basis.

Q: How much cash did Resmed return to shareholders in fiscal 2026?

A:Resmed returned more than $1.0 billion to shareholders through share repurchases and dividends during fiscal 2026, an increase of more than 70% on the prior year.

Q: Where is Resmed listed?

A:Resmed is listed on the New York Stock Exchange and the Australian Securities Exchange under the code RMD.

Q: Who is Resmed's Chairman and CEO?

A:Mick Farrell is Resmed's Chairman and CEO, as identified in the company's fourth quarter fiscal 2026 results announcement.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.